PSPablo Selvi Sabater

Pablo Selvi Sabater

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Selvi Sabater has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Two possible cases of erenumab‐induced xerostomia

    by Pablo Selvi‐Sabater, Miguel Angel Carvajal‐Sanchez, Francisco Javier Carrera‐Hueso

    What is known and objective Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug. Case summary We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented with dry mouth after the first and second dose. What is new and conclusion Xerostomia is not described as an adverse reaction in the drug's technical datasheet. A search was made in PubMed including ‘erenumab’, ‘fremanezumab’, ‘galcanezumab’, ‘xerostomia’, and no results were found. It is necessary to identify this potential adverse reaction in order to estimate its prevalence and possible impact on patients’ quality of life.


  • Open Access

    Protocolo de desensibilización a levofloxacino en paciente con infección osteoarticular. A propósito de un caso

    by P Selvi Sabater, O Montero Pérez, Jm Fajardo Picó

    RESUMEN Las reacciones alérgicas y cutáneas para fluoroquinolonas las presentan entre el 0,4% y el 2,2% de los pacientes. Se presenta un protocolo de desensibilización por vía intravenosa que se desarrolla en 4 horas con dosis de 0,05 mg hasta una dosis acumulada de 750 mg.

  • Cyclosporin-induced thrombotic thrombocytopenic purpura. Report of three cases

    by Pablo Selvi Sabater, Alberto Espuny Miró, Angela Maria Rizo Cerdá, José Enrique de la Rubia Orti

  • Púrpura trombótica trombocitopénica inducida por ciclosporina. Estudio de 3 casos

    by Pablo Selvi Sabater, Alberto Espuny Miró, Angela Maria Rizo Cerdá, José Enrique de la Rubia Orti


  • Open Access

    PKP-025 Effect of antiangiogenic treatments on biomarkers of oxidative stress in patients with age related macular degeneration

    by N Manresa-Ramón, J Mulero, P Zafrilla, M Losada, I Sánchez-Martinez, Mt Alonso-Dominguez, I De Gorostiza-Frias, P Selvi-Sabater, A Rizo-Cerda, Mdc Sánchez-Mulero

    Background Many authors have hypothesised that oxidative stress and exudative age related macular degeneration (AMD) share common antecedents and proposed that novel biomarkers associated with oxidative stress should be evaluated for their potential relationship with AMD. Purpose To analyse the effect of anti-VEGF therapy as biomarkers of oxidative stress in patients with AMD. Material and methods 73 patients with exudative AMD with no previous anti-VEGF treatment were treated with two anti-VEGF treatments: ranibizumab and pegaptanib. Average age was 71 years (55–82) and there were 40 women and 33 men. Patients were selected in the ophthalmology service. 37 patients received 0.3 mg of pegaptanib (every 6 weeks) and 36 patients received 0.5 mg of ranibizumab (every 4 weeks). The follow-up was 6 months. AMD patients were diagnosed and underwent an eye examination consisting of the following tests: corrected visual acuity-far/near; biomicroscopy of anterior segment; intraocular pressure measurement; retinography, angiography; and optical coherence tomography (OCT). Blood samples were collected from the median cubital vein. Parameters were determined before and after antiangiogenic therapy: total antioxidant activity (TAS), reduced and oxidised glutathione (GSH/GSSH), glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD) and protein carbonyl groups. The parameters were measured using the following methods: ORAC, colorimetric determination, Plagia and Valentine, Anderson, Randox and ELISA kit, respectively. Results The average results were (pegaptanib and ranibizumab, respectively): TAS (166.6 ± 20.4 µM Trolox and 202.4 ± 27.4 µM Trolox), GSH/GSSH (8.2 ± 1.4 µM and 6.2 ± 1.1 µM), GPx (7149.1 ± 2120 U/L and 7328.1 ± 1954 U/L), GR (54.1 ± 3.4 U/L and 50.6 ± 2.9 U/L), SOD (885.8 ± 25.4 Ug/Hb and 815.8 ± 75.8 Ug/Hb), carbonyl groups (72.1 ± 7.0 µmol/mg and 68.3 ± 4.1 µmol/mg). After antiangiogenic therapies, all average values except carbonyl groups decreased slightly but there were no significant differences. However, the average value of carbonyl groups was increased but there were no significant differences. Conclusion There was no statistically significant difference in the results but pegaptanib and ranibizumab may disturb the homeostatic maintenance of oxidative stress. References and/or Acknowledgements Pujol-Lereis LM. Interrelation between oxidative stress and complement activation in models of age-related macular degeneration. Adv Exp Med Biol 2016;854:87-93. Stress oxidative and age related macular degeneration. Induced oxidative stress: role in diseases and biological effects. Nova Science Publishers, 2013. References and/or AcknowledgementsThe authors acknowledge the collaboration of UCAM. No conflict of interest.

  • DI-095 Possible telaprevir-induced pancreatitis. A case study

    by P Selvi-Sabater, Am Rizo-Cerda, I Sanchez-Martinez, N Manresa-Ramon, B Arribas-Diaz, Mt Alonso-Dominguez, I Gorostiza-Frias, Mm Sanchez-Catalicio, Jc Titos-Arcos, A Espuny-Miró

    Background Telaprevir is one of the new drugs for chronic hepatitis C genotype 1. As it is a new drug is necessary to be aware of the emergence of new adverse reactions that may not be included in the SPC. Purpose To investigate possible severe adverse reactions not mentioned in telaprevir’s SPC. Materials and methods Descriptive and retrospective clinical case. Data were obtained by review of the patient medical history, Savac and Selene software and laboratory data. Results Fifty-seven-year-old male with HCV genotype 1a/1c. It was decided to start his first treatment for hepatitis C with ribavirin (RBV) 400 mg/12 h, Peg-interferon (P-INF) alfa 2a 180 mcg/week and telaprevir 750 mg/8 h. In week 8 of treatment he was admitted with symptomatology compatible with pancreatitis. Amylase 1888 IU/L appeared in laboratory data. Absolute diet, analgesic and antiemetic measures were established. The patient was discharged a week after admission with an amylase of 173 IU/L. The next day he was admitted with an amylase of 3406 IU/L and the same symptoms. Telaprevir was suspended (week 9 of treatment) in case it could be the cause, and he continued with P-INF and RBV. The patient was discharged 5 days later with an amylase of 365 IU/L. The Karch-Lasagna modified algorithm established as “possible” the relationship between pancreatitis and telaprevir. Conclusions A MEDLINE search was performed on 17.01.13 with the words “telaprevir” “pancreatitis” “abdominal pain” or “amylase” and we did not find any results that evidenced pancreatitis caused by telaprevir. A temporal association existed between drug use and pancreatitis symptoms as well as between telaprevir suspension and the patient’s improvement. Therefore, we concluded that telaprevir could have caused acute pancreatitis in this patient. No conflict of interest.


  • CP-136 Subjective improvement in patients treated with autologous serum eyedrops

    by P Selvi-Sabater, Am Rizo-Cerda, I Sanchez-Martinez, N Manresa-Ramon, Mm Sanchez-Catalicio, Jc Titos-Arcos, I Sanchez-Quiles, Mt Alonso-Dominguez, I Gorostiza-Frias, A Espuny-Miro

    Background Autologous serum eye drop treatment is a common practice in the treatment of several ocular pathologies that require relatively frequent blood draws. Purpose To study the symptom improvement perceived by patients after treatment with autologous serum 20% and overall satisfaction with such treatment. Materials and methods Observational, retrospective and descriptive study in eye disease patients (GVHD, dry eye, etc.) with autologous serum 20% eye drops in 2011 and 2012. The information was compiled by the SAVAC and SELENE prescribing systems and reviewing medical records in addition to telephone surveys of patients. Reviewed symptoms were: red eye, dry eye, inflammation, rheum, foreign body, itching/burning, tearing, photophobia, blurred vision and eye heaviness. Results A total of 15 patients (53% male) with a median age of 58 years were studied, of whom 11 (73%) had red eye, 13 (87%) dry eye, 6 (40%) inflammation, 5 (33%) rheum, 11 (73%) foreign body, 14 (93%) itching/burning, 1 (7%) tearing, 13 (87%), photophobia, 10 (67%), blurred vision, 5 (33%) eye heaviness. Of patients who experienced these symptoms, 64% of patients with red eye, 46% with dry eye, 50% with inflammation, 80% with rheum, 82% with foreign body, 64% with itching/burning, 15% with photophobia, 50% with blurred vision and 40% with eye heaviness considered they had improved and the tearing-eyed patient did not improve. Conclusions Symptoms that improved in a greater number of patients were sensation of foreign body, itching/burning eye and red eye. On the other hand, some symptoms such as photophobia, tearing and dry eye improved in only a small number of patients. Furthermore, 80% of patients said the perceived subjective improvement in symptoms was worthwhile, compared to the discomfort of blood draws. No conflict of interest.

  • CP-125 Collaboration of the pharmacist in palliative care: analysis of patients admitted and therapeutic equivalents suggested

    by Am Rizo Cerdá, N Manresa Ramon, P Selvi Sabater, Mm Sanchez Catalicio, A Boso Ribelles, I Sanchez Martinez, I De Gorostiza Frias, Jc Titos Arcos, I Sanchez Quiles, M Alonso Dominguez

    Background Pain is a common symptom that leads terminally ill patients to an emergency department. Opioids have a critical place in the management of terminal pain. Purpose To investigate the characteristics of patients admitted for palliative care and treatments prescribed for making pain bearable and to develop query tables on the dosage and exchange of opioids. Materials and methods The data of all the patients admitted to the hospital for palliative care from January to May 2012 (32 patients) were examined in order to study their demographics, admission date, sex, age, length of hospitalisation, reason for admission, the main disease, comorbidities, treatment used for pain and frequency of rescue from pain. Finally, we undertook a bibliographic review of the use of opioids for pain. Results 68.7% of enrolled patients were men, with a mean age of 75.87 years overall. 75% of patients admitted had cancer, the other patients (25%) had chronic obstructive pulmonary disease. The most common comorbidities were hypertension (27%), type II diabetes (17%), heart disease (16%) and dyslipidaemia (13%). 47% of patients experienced pain during admission, which was controlled in 67% of cases with strong opioids, 27% with NSAIDs, and 6% with weak opioids. 33% of patients required rescue medicines, with an average of less than two rescues a day. Three tables were developed showing doses, exchange and opioid rescue and were distributed throughout the hospital. Conclusions Most of the patients admitted had cancer and their pain was controlled with morphine. On average they needed fewer than two daily rescues, which could indicate that the pain was controlled. The proposed dosing and opioid exchange tables, and with the Palliative Care Unit agreement, helping to better management and safety in the administration of these drugs in the hospital. No conflict of interest.

  • Open Access

    PHC-026 Tacrolimus and Imatinib Interaction. A Case Study

    by P Selvi-Sabater, Am Rizo-Cerda, B Arribas-Diaz, A Morego-Soler, A Bosó-Ribelles, MC Sánchez-Mulero, I Sánchez-Martinez, N Manresa-Ramón, A Espuny Miro, C Castilla-Llorente

    Background Tacrolimus is a drug metabolised by CYP3A4. Since imatinib increases the plasma concentrations of simvastatin, a CYP3A4 substrate, this indicates that it is an inhibitor of this enzyme and may affect other drugs. Purpose To describe the possible interaction between imatinib and tacrolimus that result in increased blood levels of Tacrolimus. Materials and Methods Information was collected through the SAVAC and SELENE computer systems and reviewing patient history. The variables compiled were tacrolimus blood levels, dose and dose regimen. Results The patient had an allogeneic blood stem cells transplant from an unrelated donor, HLA and ABO compatible, presenting cutaneous sclerodermiform graft versus host disease (GVHD) on tacrolimus (2 mg/12 h) treatment and blood levels around 4 ng/ml for 12 weeks. After starting treatment with imatinib, in the following five tests tacrolimus levels ranged from 5.8 ng/ml to 8.9 ng/ml with no change in the dose of tacrolimus. After 45 days of treatment imatinib was suspended and tacrolimus levels recorded in the following test after discontinuation of imatinib fell to around 4 ng/ml. Conclusions The increase in tacrolimus blood levels, without changing the dose, supports the possible interaction between imatinib and tacrolimus. No conflict of interest.